levofloxacin has been researched along with Periphlebitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basile, G; Cucinotta, D; Fusco, S; Gambadoro, N; Previti, M; Reitano, F; Russo, G | 1 |
| Kilic, B; Kruse, M; Stahlmann, R | 1 |
| Flick, B; Kilic, B; Kruse, M; Stahlmann, R | 1 |
3 other study(ies) available for levofloxacin and Periphlebitis
| Article | Year |
|---|---|
Severe hypoglycemia associated with levofloxacin in a healthy older woman.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Blood Glucose; Female; Humans; Hypoglycemia; Levofloxacin; Ofloxacin; Phlebitis | 2013 |
The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926).
Topics: Anti-Bacterial Agents; Cell Adhesion Molecules; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Erythromycin; Flow Cytometry; Humans; Levofloxacin; Ofloxacin; Phlebitis; Virginiamycin | 2006 |
Effect of quinupristin/dalfopristin on 3T3 and Eahy926 cells in vitro in comparison to other antimicrobial agents with the potential to induce infusion phlebitis.
Topics: Animals; Anti-Bacterial Agents; BALB 3T3 Cells; Cell Survival; Dose-Response Relationship, Drug; Endothelial Cells; Erythromycin; Fibroblasts; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Levofloxacin; Mice; No-Observed-Adverse-Effect Level; Ofloxacin; Phlebitis; Reproducibility of Results; Toxicity Tests; Virginiamycin | 2007 |